



truscreen
a world without
cervical cancer

NZX/ASX Announcement

30 May 2023

TruScreen FY23 Preliminary Results

(all numbers in New Zealand Dollars)

Highlights

- Despite COVID interruptions in China and Vietnam, product revenues were in line with prior year, with 7% growth in H2 YOY
- Device sales up 88% YOY with 49 units spread across China, Vietnam, Mexico, Russia. Device installations increase by 15% YOY to 217
- Major breakthroughs in China with recommendations in joint peak organisations¹ Blue Paper and CSCCP Guideline
- Outstanding clinical results from Saudi Arabia clinical trial

Cervical cancer technology company **Truscreen Group Limited (ASX/NZX: TRU)** (the Company) has released its preliminary unaudited financial results for the year ended 31 March 2023.

Financial Results for the year ended 31 March 2023

Truscreen generated product sales in line with the prior year at \$1.7m (2022: \$1.7m).

As markets recovered post COVID TruScreen saw renewed demand for its TruScreen Cervical Cancer Screening Device from China, Vietnam, Mexico and Russia. The extended lockdown in China resulted in reduced number of tests in that market, impacting on overall SUS unit sales which declined by approximately 9%.

Other income decreased by 44% to \$0.54m (2022: \$0.97m) given a decrease in the research and development tax offset, and a 23% fall attributable to the removal of Australian government COVID assistance.

Total overhead expenses, excluding depreciation, amortisation and impairment declined to \$3.3m (2022: \$3.9m), attributable to a reduction in research and development given that the product is now more mature and robust.

The Company incurred an operating loss, before depreciation, amortisation and impairment, of \$2.3m (2022: loss \$2.5m), a 6% improvement on the prior year. Total loss for the year was \$2.4m (2022: \$7.9m), with the previous year including a non-cash provision for depreciation and impairment of the remaining carrying value of non-current assets in that year in the amount of \$5.4m.

While the global certainties have reduced your Board has determined that given ongoing the level of uncertainty that exists in markets in which it distributes its product, namely Russia and Eastern Europe, that the carrying value of non-current assets, including those acquired this year, remain fully impaired.


¹ Chinese Association of Gynaecologists Oncologists (COGA), Cervical Cancer Prevention and Control Research Committee of China, Women and Children's Health Research Institute, Cancer Prevention and Control Professional Committee of China Preventive Healthcare Association, National Healthcare Industry Entity Management Association, and the Genital Health Division of China Population Culture Promotion Association.

The provision for impairment, will be reviewed as uncertainties recede at future balance dates and reversed where applicable. The provision is non-cash and has no impact on the operations of the Company.


Net operating cash outflow for the year was lower at \$2.2m (2022: \$2.5m) reflecting higher receipts from customers and lower costs.

As at 31 March 2023, Truscreen had cash and cash equivalents of \$2.2m (2022: \$2.8m).

NZ\$ Revenue by Year



SUS Unit Sales By Year





truscreen
a world without
cervical cancer

Operational Key Performance and Update

Highlights of the 2023 financial year.

- ✓ TruScreen China business to be significantly bolstered with recognition in the China Blue Paper and endorsement from Chinese Society for Colposcopy and Cervical Pathology (CSCCP)
- ✓ China ramps up for Health Check centres
- ✓ Zimbabwe government continues roll out of the TruScreen program
- ✓ Outstanding clinical evaluation results from Saudi Arabia
- ✓ Russia expands operations into Kazakhstan
- ✓ Vietnam demonstrating a positive trajectory with further hospital approvals
- ✓ Mexico opens cervical cancer screening centre
- ✓ TruScreen hosts first Global Medical Symposium and readies for Medical Device Regulation

China Recognition in China Blue Paper and Endorsement from CSCCP

Subsequent to year end TruScreen was recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized Prevent and Treatment”. Blue Papers are promulgated to act as the definitive position on leading edge developments in all industries in China and are recognised as an endorsement by the experts and leaders in the relevant field.

The publication presents a consensus on the most successful and innovative technologies and methods to eradicate cervical cancer in China, in line with the World Health Organisation (WHO) strategy. The paper was the result of four years of research and collaboration by many experts in gynaecology, including a number of leaders (1) in the field who attended the publication launch.

The Blue Paper specifically highlights TruScreen in a section titled “Artificial Intelligence Technology For Cervical Cancer Screening”, describing it’s origin, substantial clinical trials, and the benefits of using TruScreen as a standalone primary cervical cancer screening method, which has demonstrated superior sensitivity and specificity results, in comparison to screening of LBC and HPV.

Separately, the TruScreen technology has also been endorsed in CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline, one of the most important specialist medical clinical guidelines governing management of cervical cancer.

CSCCP’s decision to include TruScreen technology in its new Guideline emphasises the role of new technology in a booming Chinese healthcare sector. The decision is based on the body of evidence supporting TruScreen clinical use world-wide and after extensive consultations with healthcare practitioners and decision makers.

CSCCP is a member of IFCPC (The International Federation of Cervical Pathology and Colposcopy) which is dedicated to reducing the burden of cervical cancer worldwide. The guideline issued by CSCCP is a leading clinical standard for doctors and other healthcare providers as well as government bodies.

China, after the COVID lockdown years, is now seeing a strong pipeline of significant growth opportunities. This includes 7 hospital tenders won with 13 installations pending, 23 hospitals where TruScreen has been approved and waiting for tender outcomes, and 78 hospitals where Obstetric and Gynecologic Department acceptance have been received and are waiting for the next stage of hospital approval.

China distributor, Beijing Siweixiangtai Tech Co. Ltd (SWXT), placed an order for 40 TruScreen cervical cancer screening devices for installation into China's growing public Health Check Sector late in the financial year, with delivery of the devices now having been completed in April and May 2023. This followed the first installation having been achieved at The People's Liberation Army General Hospital, one of the leading health check centers in the country, in February 2023.

Zimbabwe government continues roll out of the TruScreen program

TruScreen successfully secured a tender for the supply of a further 10,800 SUS (Single Use Sensor) which were shipped in March 2023, with the program due to recommence in May 2023.

TruScreen's screening program in Masvingo Province is a collaborative effort between the Ministry of Health and Child Care, National AIDS Council, and local health partners. The program aims to provide screening services to women in remote and underserved communities, where access to healthcare is often limited. The screening program, which began in 2022, has already screened over 10,000 women in Masvingo Province.

Outstanding clinical evaluation results from Saudi Arabia

The leading private medical services provider in Saudi Arabia, Dr. Sulaiman Al-Habib Medical Group (SHMG), completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC) during the year.

A cohort of 507 women were examined with TruScreen and LBC across multiple medical centres of SHMG. The preliminary results indicated TruScreen's sensitivity at 83.3% (LBC: 66%) and specificity at 95% (LBC 98%).



truscreen
a world without
cervical cancer

Russia expands operations into Kazakhstan

TruScreen's Russia distributor JSC IMSystems extended its presence to Kazakhstan during the year, which will now be the base of expansion by IMSystems to other Central Asian countries. Kazakhstan has a population of 18 million spread over an area of 2.7 million square kilometres (the 9th largest country in the world). Central Asian doctors and healthcare professionals are mostly trained in Russian universities and hospitals.

On the strength of our Russian distributors expansion into Kazakhstan and to accelerate screening programmes in Russia and neighbouring Central Asian countries, JSC IMSystems received 11 TruScreen cervical cancer screening devices and 6,120 SUS during the year.

Vietnam demonstrating a positive trajectory with further hospital approvals

TruScreen anticipates that Vietnam will become a market of major focus with significant potential.

A TruScreen seminar hosted by Tu Du Hospital, the most influential gynaecological hospital in South Vietnam, was held during the year receiving substantial interest, being attended by over 100 doctors.

TruScreen has achieved MOH approval for a number of the most influential hospitals in Vietnam and is expecting to receive local accreditation shortly, thereby removing the requirement for individual hospitals to seek prior MOH approval, which will shorten the sales cycle.

Mexico opens cervical cancer screening centre

TruScreen established a cervical cancer screening centre in a new clinic in Ciudad de Mexico (Mexico City) operated by leading healthcare provider Mexpharm Medical Clinical during the year.

The centre run by Mexpharm Medical Clinical, a leader in healthcare care in Mexico, showcases TruScreen's medical technology, acts as a training centre, and provides screening services to the local population. Mexico has a large addressable market with a population of more than 65 million being female, of whom around half fall within the prime cervical cancer screening age of 25-64 years.

TruScreen hosts Global Medical Symposium and readies for new global Medical Device Regulation

TruScreen completed its first global virtual medical symposium to key opinion leaders from 7 countries, on cervical cancer screening during the year.

The medical symposium was chaired by Professor Neville Hacker, one of the world leaders in gynaecology-oncology, had 132 registrations from Key Opinion Leaders from China, Mexico, Russia, Poland, Vietnam, Zimbabwe and Saudi Arabia. The medical symposium enabled professional discussions on TruScreen and its current clinical data and presented the success in cervical cancer screening programs in several countries.



truscreen
a world without
cervical cancer

TruScreen has expended significant effort during the year in preparing for the Medical Device Regulation (MDR). MDR is a new regulatory framework that replaced the Medical Device Directive (MDD) for medical devices being made and/or sold in the European Union. The MDR aims to strengthen the safety and efficacy of medical devices, improve patient safety, and enhance transparency and accountability in the medical device industry. The MDR introduces more stringent requirements for manufacturers, including increased clinical evidence requirements, stricter pre-market controls and post-market surveillance requirements, and new rules for economic operators, such as importers and distributors.

TruScreen has also expended significant effort in finalising its Chinese regulatory (NMPA) approval. In addition to providing approval for the latest TruScreen device updates, this variation will also include recertification to the updated NMPA standards.

Corporate

Appointment of CEO

The Company appointed Dr. Beata Edling as CEO in October 2022. Dr Edling is an experienced executive who previously led large and small Medical Affairs Teams and commercialised numerous medical products with global pharmaceutical companies, Sanofi-Aventis, Shire, Eli Lilly and Amgen for Australia and New Zealand. Dr Edling was previously a Non-Executive Director of ASX listed Noxopharm Limited.

Dr. Edling holds a MD from the Medical University, Gdansk, Poland, and has completed part 1 of her Fellowship with Royal College of Surgeons, Australia. Dr Edling completed her PhD at the University of New South Wales, Australia, has a MBA from Sydney's Australian Graduate School of Management, is multi-lingual and speaks several European languages

Capital Raising

The Company raised approximately \$1.6m, before costs in March 2023, through a placement of \$600,000 and \$1 million through 1 for 5 pro rata renounceable rights issue. In total the Company issued 53,775,755 new shares at \$0.03 each.

This announcement approved for release by the Board.

-ENDS-

For personal use only



truscreen
a world without
cervical cancer

For more information, visit www.truscreen.com or contact:

Beata Edling
Chief Executive Officer
juliethull@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening tool for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Zimbabwe, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

In FY22, over 170,000* TruScreen examinations were performed and over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer®".

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*

For personal use only



truscreen
a world without
cervical cancer

Glossary:

Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a microscope. <https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/pap-test>

LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be done at the same time, such as the human papillomavirus (HPV) test <https://www.cancer.net/cancer-types/cervical-cancer/diagnosis>

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be done on a sample of cells which a person can collect on their own. <https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention>

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence or absence of a condition. If individuals who have the condition are considered "positive" and those who don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives and specificity is a measure of how well a test can identify true negatives:

- **Sensitivity** (true positive rate) is the probability of a positive test result, [conditioned](#) on the individual truly being positive.
- **Specificity** (true negative rate) is the probability of a negative test result, conditioned on the individual truly being negative ([Sensitivity and specificity – Wikipedia](#)).

For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia, please see useful links:

New Zealand: [National Cervical Screening Programme | National Screening Unit \(nsu.govt.nz\)](#)

Australia: [Cervical cancer | Causes, Symptoms & Treatments | Cancer Council](#)

Results for announcement to the market		
Name of issuer	Truscreen Group Limited	
Reporting Period	12 months to 31 March 2023	
Previous Reporting Period	12 months to 31 March 2022	
Currency	NZ Dollars	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$1,662	(1%)
Total Revenue	\$1,662	(1%)
Net profit/(loss) from continuing operations	\$(2,401)	+70%
Total net profit/(loss)	\$(2,401)	+70%
Interim/Final Dividend		
Amount per Quoted Equity Security	N/A	
Imputed amount per Quoted Equity Security	N/A	
Record Date	N/A	
Dividend Payment Date	N/A	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.006	\$0.0094
A brief explanation of any of the figures above necessary to enable the figures to be understood	See attached announcement	
Authority for this announcement		
Name of person authorised to make this announcement	Guy Robertson Chief Financial Officer	
Contact person for this announcement	Guy Robertson	
Contact phone number	+61 407 983 270	
Contact email address	guyrobertson@truscreen.com	
Date of release through MAP	30 May 2023	

Unaudited financial statements accompany this announcement.

TRUSCREEN GROUP LIMITED

Preliminary Final Report Consolidated Financial Statements - Unaudited

Currency is New Zealand Dollars

For the Year Ended 31 March 2023

Contents

Consolidated Summary of Profit or Loss and Other Comprehensive Income	2
Consolidated Statement of Financial Position	3
Consolidated Statement of Changes in Equity	4
Consolidated Statement of Cash Flows	5
Notes to the Financial Statements	6

TRUSCREEN GROUP LIMITED
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2023

	Note	2023	2022
		\$	\$
Revenue from the sale of goods	3	1,662,619	1,678,465
Other income	3	540,016	973,914
Purchases of inventory		(1,202,628)	(1,155,725)
Employee benefit expenses and directors' fees		(876,849)	(991,911)
Administration		(415,296)	(347,807)
Research and development expenses		(864,074)	(1,498,629)
Rent		(60,959)	(54,139)
Travel		(62,544)	(4,969)
Marketing & product approvals		(722,256)	(716,923)
Insurance		(139,633)	(116,191)
Shareholder relations & services		(155,664)	(117,877)
Amortisation & depreciation		-	(592,715)
Write off of obsolete inventory		-	(181,217)
Provision for impairment plant and equipment		(49,700)	(198,847)
Provision for impairment of intangible assets		-	(4,423,287)
Share based payments		(54,873)	(144,813)
Loss before income tax		<u>(2,401,840)</u>	<u>(7,892,672)</u>
Income tax expense		-	-
Loss for the period		<u>(2,401,840)</u>	<u>(7,892,672)</u>
Other comprehensive income			
Item that may be reclassified subsequently to profit or loss			
Exchange differences on translating foreign subsidiary operations		1,736	(166,281)
		<u>1,736</u>	<u>(166,281)</u>
Total comprehensive loss for the period		<u>(2,400,104)</u>	<u>(8,058,953)</u>
Basic and diluted loss per share (cents)	4	<u>(0.66)</u>	<u>(2.18)</u>

TRUSCREEN GROUP LIMITED
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2023

	Note	2023 \$	2022 \$
CURRENT ASSETS			
Cash and cash equivalents		2,160,468	2,797,004
Other receivables		336,700	601,554
Trade receivables		170,311	275,447
Goods and services tax recoverable		33,902	36,782
Inventories		563,441	496,887
Other current assets – prepayments		205,361	179,270
TOTAL CURRENT ASSETS		<u>3,470,183</u>	<u>4,386,944</u>
NON-CURRENT ASSETS			
Plant and equipment		-	-
Intangible assets		-	-
TOTAL NON-CURRENT ASSETS		<u>-</u>	<u>-</u>
TOTAL ASSETS		<u>3,470,183</u>	<u>4,386,944</u>
CURRENT LIABILITIES			
Trade and other payables		800,255	807,374
Provision for employee benefits		88,547	140,385
TOTAL CURRENT LIABILITIES		<u>888,802</u>	<u>947,759</u>
NON-CURRENT LIABILITIES			
Provision for employee benefits		39,357	44,134
TOTAL NON-CURRENT LIABILITIES		<u>39,357</u>	<u>44,134</u>
TOTAL LIABILITIES		<u>928,159</u>	<u>991,893</u>
NET ASSETS		<u>2,542,024</u>	<u>3,395,051</u>
EQUITY			
Issued capital	5	36,097,125	34,550,048
Share option reserve	5	144,813	450,813
Foreign currency translation reserve		(379,108)	(380,844)
Accumulated losses		<u>(33,320,806)</u>	<u>(31,224,966)</u>
Total Equity		<u>2,542,024</u>	<u>3,395,051</u>

TRUSCREEN GROUP LIMITED
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2023

	Note	Share Capital \$	Accumulated Losses \$	Foreign Currency Translation Reserve \$	Option Reserve \$	Total \$
Balance at 1 April 2022		34,550,048	(31,224,966)	(380,844)	450,813	3,395,051
Loss for the year to 31 March 2023		-	(2,401,840)	-	-	(2,401,840)
Exchange differences on translating foreign subsidiary operations		-	-	1,736	-	1,736
Total comprehensive income for the year		-	(2,401,840)	1,736	-	(2,400,104)
Transactions with owners, in their capacity as owners						
Issue of shares	5	1,613,273	-	-	-	1,613,273
Share issue costs	5	(66,196)	-	-	-	(66,196)
Transfer from share based payments		-	306,000	-	(306,000)	-
Total transactions with owners		1,547,077	306,000	-	(306,000)	1,547,077
Balance at 31 March 2023		36,097,125	(33,320,806)	(379,108)	144,813	2,542,024

	Note	Share Capital \$	Accumulated Losses \$	Foreign Currency Translation Reserve \$	Option Reserve \$	Total \$
Balance at 1 April 2021		34,550,048	(23,332,294)	(214,563)	306,000	11,309,191
Loss for the year to 31 March 2022		-	(7,892,672)	-	-	(7,892,672)
Exchange differences on translating foreign subsidiary operations		-	-	(166,281)	-	(166,281)
Total comprehensive income for the year		-	(7,892,672)	(166,281)	-	(8,058,953)
Transactions with owners, in their capacity as owners						
Share based payments		-	-	-	144,813	144,813
Total transactions with owners		-	-	-	144,813	144,813
Balance at 31 March 2022		34,550,048	(31,224,966)	(380,844)	450,813	3,395,051

TRUSCREEN GROUP LIMITED

**CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2023**

	Note	2023	2022
		\$	\$
CASH FLOW FROM OPERATING ACTIVITIES			
Cash received from customers		1,790,550	1,434,264
Cash paid to suppliers and employees including GST		(4,483,553)	(4,586,932)
Cash received from research and development tax offset		627,982	620,888
Government subsidies		-	123,535
Short-term lease payments not included in lease liability		(131,619)	(123,775)
Interest received		2,854	323
Net cash from operating activities	6	<u>(2,193,786)</u>	<u>(2,531,697)</u>
CASH FLOW TO INVESTING ACTIVITIES			
Purchase of plant and equipment		<u>(49,700)</u>	<u>(2,662)</u>
Net cash to investing activities		<u>(49,700)</u>	<u>(2,662)</u>
CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issue of shares		1,613,273	-
Share issue costs		<u>(66,196)</u>	<u>-</u>
Net cash from financing activities		<u>1,547,077</u>	<u>-</u>
Net decrease in cash and cash equivalents		(696,409)	(2,534,359)
Cash and cash equivalents at the beginning of the financial year		2,797,004	5,255,074
Effects of exchange rate changes on cash and cash equivalents		<u>59,873</u>	<u>76,289</u>
Cash and cash equivalents at the end of the financial year		<u>2,160,468</u>	<u>2,797,004</u>

For personal use only

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General Information

These consolidated financial statements and notes represent those of Truscreen Group Limited (formerly Truscreen Limited) and its subsidiaries (the “Group”). References to “Truscreen” is used to refer to Truscreen Group Limited (the “Company”).

The parent company, Truscreen Group Limited, is the ultimate legal parent company of the Group and is a limited liability company incorporated and domiciled in New Zealand. It is registered under the Companies Act 1993. Truscreen is listed on the NZX and on the ASX as an ASX Foreign Exempt Listing. Truscreen is a FMC reporting entity under Part 7 of the Financial Markets Conduct Act 2013.

The registered office of the Company is Level 6 Equitable House, 57 Symonds St, Grafton, Auckland 1010, New Zealand. The Group is engaged in the business of the development, manufacture and sale of cancer detection devices and systems.

Basis of Preparation

These financial statements have been prepared under the historical costs convention, modified by the revaluation of certain assets and liabilities.

The principal accounting policies adopted in the preparation of the financial report are unchanged from the Interim Financial Statements for the period ended 30 September 2022 and Annual Financial Statements for the year ended 31 March 2022. These policies have been consistently applied to all the periods presented, unless otherwise stated.

The financial statements have been rounded to the nearest dollar.

NOTE 2. SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS

The Company makes estimates and assumptions concerning the future that affects the amounts reported in the financial statements. Estimates and judgments are continually evaluated and based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing material adjustments to the carrying amounts of assets and liabilities within the next financial year are discussed below:

- *Intangibles*

The carrying value of intangibles include acquired intellectual property and development costs capitalised in accordance with the accounting policy for research and development.

The intangibles were fully written off in the previous year.

Given the ongoing significant uncertainty associated with macro-economic events, the Directors have determined that the intangibles should remain fully impaired as at 31 March 2023.

NOTE 3. REVENUE

	2023	2022
	\$	\$
Sales revenue - sale of goods ¹		
Wholesalers/distributors	1,415,542	1,462,566
Direct to customer	247,077	215,899
	<u>1,662,619</u>	<u>1,678,465</u>
Other income		
Research and development tax offset ²		
- Current year	345,901	593,197
- Prior year adjustment	31,143	48,830
	<u>377,044</u>	<u>642,027</u>
Interest received	3,303	372
Miscellaneous income	39,084	-
Foreign exchange gain	120,585	103,348
Government assistance and grants	-	228,167
	<u>540,016</u>	<u>973,914</u>

NOTE 4. EARNINGS PER SHARE

	2023	2022
Basic and Diluted loss per share:		
Net loss attributable to shareholders	(2,401,840)	(7,892,672)
Weighted average number of ordinary shares on issue	364,192,230	362,866,253
Basic and diluted loss per share (cents) (based on weighted average number of shares on issue)	<u>(0.66)</u>	<u>(2.18)</u>

NOTE 5. ISSUED CAPITAL

a) Ordinary Shares

Group	2023 Number	2023 \$	2022 Number	2022 \$
Balance at beginning of the year of fully paid ordinary shares	362,866,253	34,550,048	362,866,253	34,550,048
Ordinary shares issued				
Share issue - placement	20,000,000	600,000	-	-
Share issue – rights issue	33,775,755	1,013,273	-	-
Share issue costs	-	(66,196)	-	-
Balance at 31 March	416,642,008	36,097,125	362,866,253	34,550,048

No particular number of shares are authorised. There is no par value of shares.

All issued ordinary shares carry equal rights in respect of voting and the receipt of dividends, and upon winding up rank equally with regard to the Company's residual assets.

Shares were issued during the:

a. current period:

The Company undertook a share placement and a rights issue during the year, issuing 53,775,755 shares at \$0.03 per share to raise \$1,613,273, before costs.

b. prior period:

No shares were issued in the prior period.

b) Share Options

Group	2023 Number	2023 Share Based Payments \$	Weighted Average Exercise Price	2022 Number	2022 Share Based Payments \$	Weighted Average Exercise Price
Balance at beginning of the year	14,000,000	450,813	12.5c	17,777,363	306,000	13.9c
Options issued ¹	-	-	10.0c	2,500,000	69,500	10.0c
Options issued ²	-	-	10.0c	2,500,000	75,313	10.0c
Options lapsed ³	(9,000,000)	(306,000)		(8,777,363)	-	-
Balance at end of year	5,000,000	144,813	10.0c	14,000,000	450,813	12.5c

¹Options issued 29 December 2021 to directors and employee

²Options issued 4 March 2022 to distributors

³Options lapsed exercise price of 15 cents and expiry date 27 August 2022 and in the prior year 13 cents per share and expiry date 12 July 2021.

NOTE 6. CASH FLOW INFORMATION

	2023	2022
	\$	\$
Reconciliation of cash flow from operations with loss after income tax		
Loss for the period	(2,401,840)	(7,892,672)
Adjusted for:		
Depreciation and amortisation	-	592,715
Impairment of non-current assets	49,700	4,622,134
Share based payment expense	54,873	144,813
Unrealised exchange difference arising from translating loss items at the date of transaction	(113,010)	(146,358)
Operating cash flows before working capital changes	(2,410,277)	(2,679,368)
Decrease/(Increase) in trade and other receivables	105,137	(275,447)
Decrease in goods and services taxes recoverable	2,880	7,445
Increase in prepayments	(26,092)	(73,339)
(Increase)/decrease in inventory	(66,553)	235,687
Decrease/(increase) in research and development tax offset	264,854	(43,069)
Decrease/(Increase) in trade and other payables	(7,120)	354,881
Decrease in employee liabilities	(56,615)	(58,487)
Net cash to operating activities	(2,193,786)	(2,531,697)